1. Home
  2. VITL vs ALLO Comparison

VITL vs ALLO Comparison

Compare VITL & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vital Farms Inc.

VITL

Vital Farms Inc.

HOLD

Current Price

$12.66

Market Cap

588.6M

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$2.48

Market Cap

539.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VITL
ALLO
Founded
2007
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
588.6M
539.4M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
VITL
ALLO
Price
$12.66
$2.48
Analyst Decision
Strong Buy
Buy
Analyst Count
10
11
Target Price
$37.90
$8.40
AVG Volume (30 Days)
2.6M
4.6M
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
22.03
34.09
EPS
1.44
N/A
Revenue
$759,444,000.00
N/A
Revenue This Year
$21.13
N/A
Revenue Next Year
$18.17
$140,929.80
P/E Ratio
$8.74
N/A
Revenue Growth
25.26
N/A
52 Week Low
$12.35
$0.86
52 Week High
$53.13
$2.80

Technical Indicators

Market Signals
Indicator
VITL
ALLO
Relative Strength Index (RSI) 20.37 54.90
Support Level N/A $2.14
Resistance Level $33.73 $2.71
Average True Range (ATR) 0.90 0.23
MACD 0.19 -0.00
Stochastic Oscillator 4.76 68.33

Price Performance

Historical Comparison
VITL
ALLO

About VITL Vital Farms Inc.

Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: